EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD

Cheng-Hsien Hung iD, Fu-Yu Yang, Hung-En Huang iD, James Cheng-Chung Wei iD

Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1879-1888

DOI: 10.2215/cjn.0000001168 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.08.2026. Verfasst von Cheng-Hsien Hung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Teriparatide, Renal Insufficiency, Chronic, Osteoporosis, Bone Density Conservation Agents. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Romosozumab was associated with lower vertebral fracture risk than teriparatide in patients with osteoporosis and CKD. No significant differences were observed in nonvertebral or hip fracture risk between treatment groups. Romosozumab was associated with lower risks of major adverse cardiovascular events and myocardial infarction compared with teriparatide.

Background

Osteoporosis commonly coexists with CKD, increasing skeletal fragility and cardiovascular risk. While romosozumab shows superior fracture prevention in general osteoporosis, evidence in CKD stages 3–5 patients remains limited.

Methods

Using a target trial emulation design, we conducted a retrospective cohort study leveraging the TriNetX US research network. Patients aged 40 years or older with osteoporosis and an eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeriparatideRenal Insufficiency, ChronicOsteoporosisBone Density Conservation AgentsCardiovascular DiseasesAntibodies, MonoclonalOsteoporotic FracturesHumansFemaleAgedRetrospective StudiesMaleMiddle AgedHip FracturesSpinal FracturesTreatment OutcomeAged, 80 and overMyocardial Infarction

Stichwörter der Autor:innen

CKDchronic kidney failurechronic nephropathy

Substanzen

TeriparatideBone Density Conservation AgentsromosozumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
  • Department of Pharmacy, Changhua Christian Medical Foundation Yuanlin Christian Hospital, Yuanlin, Taiwan.
  • Department of Medical Research, Center for Health Data Science, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Cheng-Hsien Hung, Hung-En Huang, James Cheng-Chung Wei

Zitieren

APA

Hung, C. H., Yang, F. Y., Huang, H. E., & Wei, J. C. (2026). Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD. Clinical Journal of the American Society of Nephrology, 21(11), 1879-1888. https://doi.org/10.2215/cjn.0000001168

Vancouver

Hung CH, Yang FY, Huang HE, Wei JC. Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD. Clinical Journal of the American Society of Nephrology. 2026;21(11):1879-1888. doi:10.2215/cjn.0000001168

BibTeX
@article{Hung2026,
  author = {Hung, Cheng-Hsien and Yang, Fu-Yu and Huang, Hung-En and Wei, James Cheng-Chung},
  title = {Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {1879--1888},
  doi = {10.2215/cjn.0000001168}
}
Kostenlos starten →